Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A D Ho

Showing results (311-320 of 321) with videos related to

Pageof 33
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment ProgramP McLaughlin, A J Grillo-López, B K Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programP McLaughlin, A J Grillo-López, B K Link, et al.
Oncogene|September 1, 2009
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesisA Seckinger, T Meissner, J Moreaux, et al.
Immunohematology|May 7, 2021
An automated approach to determine antibody endpoint titers for COVID-19 by an enzyme-linked immunosorbent assayA D Ho, H Verkerke, J W Allen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparisonI Herth, S Dietrich, A Benner, et al.
Cancer Gene Therapy|January 19, 2008
Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancerG Kallifatidis, B M Beckermann, A Groth, et al.
Leukemia|December 2, 2014
Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trialJ Schetelig, M Schaich, K Schäfer-Eckart, et al.
Leukemia|February 25, 2017
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivoA Chaturvedi, L Herbst, S Pusch, et al.
Leukemia|March 22, 2017
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxideS Kayser, J Krzykalla, M A Elliott, et al.
Leukemia|March 27, 2004
The German competence network 'Acute and chronic leukemias'R Hehlmann, U Berger, C Aul, et al.
Pageof 33

Showing results (311-320 of 321) with videos related to

Sort By:
Pageof 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment ProgramP McLaughlin, A J Grillo-López, B K Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programP McLaughlin, A J Grillo-López, B K Link, et al.
Oncogene|September 1, 2009
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesisA Seckinger, T Meissner, J Moreaux, et al.
Immunohematology|May 7, 2021
An automated approach to determine antibody endpoint titers for COVID-19 by an enzyme-linked immunosorbent assayA D Ho, H Verkerke, J W Allen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparisonI Herth, S Dietrich, A Benner, et al.
Cancer Gene Therapy|January 19, 2008
Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancerG Kallifatidis, B M Beckermann, A Groth, et al.
Leukemia|December 2, 2014
Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trialJ Schetelig, M Schaich, K Schäfer-Eckart, et al.
Leukemia|February 25, 2017
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivoA Chaturvedi, L Herbst, S Pusch, et al.
Leukemia|March 22, 2017
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxideS Kayser, J Krzykalla, M A Elliott, et al.
Leukemia|March 27, 2004
The German competence network 'Acute and chronic leukemias'R Hehlmann, U Berger, C Aul, et al.
Pageof 33